Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dysglycemia: a key cardiovascular risk factor.

Hertzel C Gerstein1, Sarah E Capes

  • 1Department of Medicine and the Division of Endocrinology and Metabolism, McMaster University, Hamilton, Ontario, Canada. gerstein@mcmaster.ca

Seminars in Vascular Medicine
|October 14, 2005
PubMed
Summary

Elevated glucose levels, known as dysglycemia, progressively increase cardiovascular event risk, even below diabetes thresholds. Future trials will determine if glucose normalization reduces this risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interpreting apparent differences among the major colchicine trials for cardiovascular prevention: a descriptive compatibility analysis.

American heart journal·2026
Same author

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Circulation·2026
Same author

A Highly Powered Large Outcomes Randomised Controlled Trial Will Usually, but Not Always, Have Balanced Groups at Baseline.

Diabetes, obesity & metabolism·2026
Same author

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial.

Diabetes, obesity & metabolism·2026
Same author

Feasibility, reproducibility, and cold-induced energy expenditure using whole-room calorimetry in adults and children.

Journal of the Endocrine Society·2026
Same author

Impact of the COVID-19 pandemic on obesity: a prospective cohort study of the Canadian Longitudinal Study on Aging (CLSA).

BMJ open·2026

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • Diabetes mellitus is a significant independent risk factor for cardiovascular events.
  • Cardiovascular risk associated with glucose levels rises progressively from normal ranges into diabetic levels.
  • Dysglycemia, encompassing any elevated fasting or postprandial glucose, represents a continuous cardiovascular risk factor.

Purpose of the Study:

  • To highlight that cardiovascular risk escalates with rising glucose levels, not just within the diabetic range.
  • To emphasize the continuous nature of glucose as a cardiovascular risk factor, similar to established factors like age and blood pressure.
  • To address the unresolved question of whether glucose-lowering strategies mitigate cardiovascular risk in individuals with dysglycemia.

Main Methods:

Related Experiment Videos

  • This study is a review and consensus statement based on existing research and ongoing trials.
  • It synthesizes evidence on the relationship between glucose levels and cardiovascular events.
  • It discusses the implications of current understanding for clinical practice and future research.

Main Results:

  • Cardiovascular event risk increases progressively as fasting and postprandial glucose levels rise.
  • This risk escalation occurs across the spectrum from normal glucose levels to the diabetic range.
  • Dysglycemia functions as a continuous, progressive cardiovascular risk factor, akin to age, LDL cholesterol, and blood pressure.

Conclusions:

  • Dysglycemia is a continuous cardiovascular risk factor, independent of a formal diabetes diagnosis.
  • The cardiovascular benefits of normalizing glucose levels in individuals with diabetes or lesser degrees of dysglycemia require further investigation.
  • Results from ongoing international trials are anticipated to clarify the impact of glucose-lowering interventions on cardiovascular outcomes.